AZD1222 vaccine for the Prevention of COVID-19

Trial Identifier: D8111C00001
Sponsor: AstraZeneca
Collaborator:
IQVIA
Covance
NCTID:: NCT04540393
Start Date: September 2020
Primary Completion Date: December 2020
Study Completion Date: May 2022
Condition: COVID-19 Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russian Federation Moscow, Russian Federation, 117321
Russian Federation Saint Petersburg, Russian Federation, 196240
Russian Federation Saint-Petersburg, Russian Federation, 197376
Russian Federation St. Petersburg, Russian Federation, 197022